



## Breast Cancer: Molecular Basis and Translational Research

Guest Editor:

**Dr. Bora Lim**

Department of Oncology  
Medicine, Baylor College of  
Medicine, Houston, TX, USA

Deadline for manuscript  
submissions:

**closed (30 June 2022)**

### Message from the Guest Editor

Dear Colleagues,

We propose this Special Issue of “Breast Cancer: Molecular Basis and Translational Research” to cover the content about the pathogenic mechanism, novel omics-based biomarker assessment in breast cancer, and new therapeutic discoveries including pre-clinical studies. Given the importance of “bench-to-bedside translation” as a fundamental conduit of translational research in breast cancer, we will also cover topics such as liquid biopsy and other precision diagnostics in breast cancer that are under active developments. We will also include few review articles to share the current perspectives to compose the mix of original research data and reviews. We hope our Special Issue will attract studies that offer new insights into translational research in the field of breast cancer.

Dr. Bora Lim  
*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPlus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](https://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
X@Biomed\_MDPI